These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8638534)

  • 1. Phase I study of a carboplatin-cisplatin-etoposide combination chemotherapy in advanced non-small-cell lung cancer.
    Nakano H; Tsuchiya S; Takei Y; Minato K; Watanabe S; Makimoto T; Naruse I; Nomoto T; Ishihara S; Takise A; Ezawa K; Fueki N; Hoshino H; Saito R; Mori M
    Am J Clin Oncol; 1996 Jun; 19(3):245-8. PubMed ID: 8638534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
    Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
    Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer.
    Frasci G; Perillo G; Comella G; Comella P; Polverino M; Menzella G; Persico G
    Cancer; 1995 Apr; 75(7):1578-85. PubMed ID: 8826913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan.
    Katakami N; Takada M; Negoro S; Ota K; Fujita J; Furuse K; Ariyoshi Y; Ikegami H; Fukuoka M
    Cancer; 1996 Jan; 77(1):63-70. PubMed ID: 8630941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of carboplatin-cisplatin-etoposide combination chemotherapy in advanced non-small-cell lung cancer.
    Makimoto T; Tsuchiya S; Nakano H; Watanabe S; Minato K; Takise A; Ezawa K; Fueki N; Naruse I; Nomoto T; Takei Y; Ishihara S; Mori M; Saitoh R
    Am J Clin Oncol; 1997 Feb; 20(1):51-4. PubMed ID: 9020288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial substitution of cisplatin with carboplatin in combination with etoposide in advanced non-small cell lung cancer (NSCLC): a multicentric randomised phase II trial.
    Comella P; Frasci G; Panza N; De Cataldis G; Cioffi R; Curcio C; Nicolella D; Micillo E; Ianniello GP; Biondi E; Perchard J; Comella G
    Lung Cancer; 1996 Aug; 15(1):103-14. PubMed ID: 8865128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.
    Klastersky J; Sculier JP; Lacroix H; Dabouis G; Bureau G; Libert P; Richez M; Ravez P; Vandermoten G; Thiriaux J
    J Clin Oncol; 1990 Sep; 8(9):1556-62. PubMed ID: 2167953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of dose intensification with cisplatin and carboplatin plus vindesine in patients with inoperable non-small cell lung cancer.
    Nakanishi Y; Takayama K; Kawasaki M; Yatsunami J; Inutsuka S; Wakamatsu K; Tsuruta N; Hara N
    Am J Clin Oncol; 1997 Aug; 20(4):393-7. PubMed ID: 9256897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An early phase II trial combining cisplatin, carboplatin and vindesine in patients with inoperable non-small cell lung cancer].
    Haneda H; Koizumi M; Hayashi T
    Gan To Kagaku Ryoho; 2000 Feb; 27(2):227-31. PubMed ID: 10700892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-escalation study of oral etoposide and carboplatin in patients with advanced lung cancer.
    Atagi S; Furuse K; Kawahara M; Kodama N; Ogawara M; Kubota K; Matsui K; Kusunoki Y; Masuda N; Takada M; Negoro S; Fukuoka M
    Jpn J Clin Oncol; 1996 Oct; 26(5):316-21. PubMed ID: 8895671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase I clinical study of combined cisplatin and carboplatin therapy in lung cancer].
    Hayasaka S; Yoshinaga T; Kinuwaki E; Kiyama T; Fujino N
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2011-6. PubMed ID: 1417008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of unresectable non-small cell lung cancer (NSCLC) with carboplatin and chronic daily administration of oral etoposide].
    Hirabayashi M; Tanaka Y; Yoshida H; Nakagawa M; Kuno K
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):53-8. PubMed ID: 8291916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of combination chemotherapy with cisplatin, carboplatin and etoposide in small cell lung cancer.
    Sakurai M; Ichiki M; Hayashi I
    Lung Cancer; 1996 Sep; 15(2):225-32. PubMed ID: 8882989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
    Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
    Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: final analysis.
    Bardet E; Rivière A; Charloux A; Spaeth D; Ducoloné A; Le Groumellec A; Pellae-Cosset B; Henry-Amar M; Douillard JY
    Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):163-8. PubMed ID: 9212019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
    Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
    Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined carboplatin and cisplatin therapy in patients with advanced non-small cell lung cancer.
    Nakanishi R; Kume T; Mitsudomi T; Yoshimatsu T; Osaki T; Tokunaga H; Yasumoto K
    Am J Clin Oncol; 1997 Feb; 20(1):31-5. PubMed ID: 9020284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group.
    Crino L; Tonato M; Darwish S; Meacci ML; Corgna E; Di Costanzo F; Buzzi F; Fornari G; Santi E; Ballatori E
    Cancer Chemother Pharmacol; 1990; 26(1):52-6. PubMed ID: 2157554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.